Literature DB >> 702236

Activity of the alternative pathway of complement in the newborn infant.

D Adamkin, A Stitzel, J Urmson, M L Farnett, E Post, R Spitzer.   

Abstract

Levels of C3, properdin, factor B, and C3 to C9 activity were markedly reduced in cord sera taken from 94 normal newborn infants. Nevertheless, cord serum supported complete activation of its own alternative pathway by zymosan or CoF. Lysis of a target cell, however, was defective; nearly 75% of cord sera had reduced rabbit erythrocyte CH50 titers. These were partially increased by the addition of factor B and properdin, and totally restored by adding factor B, properdin, and C3 to C9. Therefore, although the alternative pathway of the neonate is intact, it appears to be limited in its ability to generate an adequate number of stable and active enzymatic sites on a target cell membrane.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 702236     DOI: 10.1016/s0022-3476(78)80895-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

2.  Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease.

Authors:  B J Potter; D J Brown; A Watson; D P Jewell
Journal:  Gut       Date:  1980-12       Impact factor: 23.059

3.  C3, factor B, alpha-1-antitrypsin in neonatal septicaemia with sclerema.

Authors:  B Pelet
Journal:  Arch Dis Child       Date:  1980-10       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.